TRUSOPT Drug Patent Profile

When do Trusopt patents expire, and what generic alternatives are available?

Trusopt is a drug marketed by Msd Sub Merck and is included in one NDA.

The generic ingredient in TRUSOPT is dorzolamide hydrochloride. There are fifteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the dorzolamide hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Trusopt

A generic version of TRUSOPT was approved as dorzolamide hydrochloride by RUBICON RESEARCH on October 28^th, 2008.

Summary for TRUSOPT

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for TRUSOPT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRUSOPT	Ophthalmic Solution	dorzolamide hydrochloride	2%	020408	1	2005-10-11

US Patents and Regulatory Information for TRUSOPT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	TRUSOPT	dorzolamide hydrochloride	SOLUTION/DROPS;OPHTHALMIC	020408-001	Dec 9, 1994		DISCN	Yes	No

International Patents for TRUSOPT

See the table below for patents covering TRUSOPT around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	1838788
Ireland	62255	Substituted aromatic sulfonamides as antiglaucoma agents
Canada	1192560	2-TRIFLUORO-(OU TRICHLORO-)-ACETYLIMINO-3-METHYL- D.SUP.2-1,3,4-THIADIAZOLINE-5-SULFONAMIDES UTILISES POUR REDUIRE LA PRESSION INTRAOCULAIRE (2-TRIFLUORO-(OR TRICHLORO-)-ACETYLIMINO-3-METHYL- D.SUP.2-1,3,4-THIADIAZOLINE-5-SULFONAMIDES USED FOR REDUCING INTRAOCULAR PRESSURE)

Supplementary Protection Certificates for TRUSOPT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0509752	SPC/GB99/043	United Kingdom		PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
0509752	C990041	Netherlands		PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
0296879	96C0003	Belgium		PRODUCT NAME: HYDROCHLORIDUM, EQ. DORZOLAMIDUM; NAT. REGISTRATION NO/DATE: 922 IS 168 F13 19951019; FIRST REGISTRATION: SE 12208 19941219

TRUSOPT Market Analysis and Financial Projection

Last updated: February 7, 2026

What Is the Investment Scenario for TRUSOPT (Dichlorphenamide)?

TRUSOPT (dichlorphenamide) is a medication primarily used to treat glaucoma and ocular hypertension. Its market dynamics depend heavily on the ophthalmology segment and the competitive landscape of similar drugs. The product holds a modest market share, with sales influenced by patent status, generic competition, and emerging therapeutic alternatives.

What Are the Key Fundamentals of TRUSOPT?

Market Position and Revenue

TRUSOPT’s revenue streams remain stable due to its long-standing approval and established prescription base. However, its sales growth is limited by the availability of generics and competition from newer agents.

• Global Sales: Estimated at around $20 million annually (2019-2021) based on IQVIA data [1].
• Market Share: It holds a small fraction of the glaucoma treatment market compared to first-line agents like prostaglandin analogues.
• Patent Status: The original patent expired in the early 2000s, with subsequent exclusivities varying by region.

Patent and Regulatory Status

• Patent Expiry: The original patent expired decades ago, allowing generic manufacturers to produce dichlorphenamide.
• Regulatory Approvals: Approved in multiple regions, including the US and Europe. Recent regulatory actions focus on establishing bioequivalence for generics.
• Orphan or Priority Designation: No, TRUSOPT does not have orphan or priority review status, limiting fast-track opportunities.

Manufacturing and Supply Chain

• Manufacturers: Multiple generic manufacturers produce dichlorphenamide after patent expiry.
• Supply Chain Risks: Minimal, as multiple suppliers exist; however, raw material costs can influence margins.

Competitive Landscape

• Direct Competitors: Several generics and other classes of glaucoma treatments.
• Innovative Alternatives: Newer drugs with longer-lasting effects or fewer side effects are capturing market share, such as prostaglandin analogues.

R&D and Pipeline Prospects

• TRUSOPT itself has limited R&D activity due to its age and generic status.
• Future pipeline developments focus on combination therapies and delivery methods rather than dichlorphenamide itself.

External Factors

• Healthcare Policies: Push toward cost-effective generics favors TRUSOPT's generic versions.
• Off-label Uses: Minimal, mostly confined to niche indications.
• Pricing and Reimbursement: Falling prices for generics impact revenue potential.

How Do Financials and Market Trends Affect Investment?

• The product’s cash flow remains steady but limited.
• The market is mature with minimal growth prospects.
• Companies with TRUSOPT assets position for cost-cutting and efficiency rather than expansion.

What Are the Risks and Opportunities?

Risks	Opportunities
Market saturation and generics	Cost savings from manufacturing
Competition from newer drugs	Potential licensing or acquisition
Regulatory shifts toward biosimilars	Growth in niche indications
Declining reimbursement rates	Extension of patent rights in certain regions

What Is the Long-term Outlook?

TRUSOPT’s future depends on the patent landscape and its ability to maintain relevance through niche indications or combination therapies. The generic market diminishes exclusive revenue, making it less attractive for investment unless tied to strategic licensing or repurposing efforts.

Key Takeaways

• TRUSOPT is a mature, off-patent drug with stable but declining sales.
• The primary revenue drivers are generic competition and pricing pressures.
• No significant pipeline activity or innovation is associated with the molecule.
• Strategic value lies in manufacturing efficiency or licensing.
• Market dynamics favor cost containment over growth.

FAQs

1. Can TRUSOPT's patent status change in the future?
No, the original patent has expired, but brand-specific formulation patents may still be in force in certain regions, which could delay generic entry.

2. How does competitive pressure impact TRUSOPT's profitability?
Generics and alternative therapies reduce prices and market share, constraining profit margins.

3. Are there any regulatory developments that might revive TRUSOPT’s prospects?
While unlikely, new indications or combination therapies could create niche markets, but none are currently active.

4. What is the outlook for TRUSOPT’s manufacturing costs?
Manufacturing costs are low due to generic competition, but raw material prices and regulatory compliance costs can influence margins.

5. Is TRUSOPT a suitable acquisition target for pharmaceutical companies?
Only if part of a broader strategy focusing on cost savings, licensing, or portfolio restructuring; its standalone value is limited.

---

References
[1] IQVIA, Global Sales Data, 2019-2021.